首页 > 最新文献

Obesity Surgery最新文献

英文 中文
Bariatric Surgery: a Commonly Effective Treatment for ADHD? 减肥手术:治疗多动症的常见有效方法?
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1007/s11695-024-07512-x
Yicheng Shen, Hengda Hu
{"title":"Bariatric Surgery: a Commonly Effective Treatment for ADHD?","authors":"Yicheng Shen, Hengda Hu","doi":"10.1007/s11695-024-07512-x","DOIUrl":"10.1007/s11695-024-07512-x","url":null,"abstract":"","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BariClip: Outcomes and Complications from a Single-Center Experience. BariClip:单中心经验的结果和并发症。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-07 DOI: 10.1007/s11695-024-07522-9
Marta Bonaldi, Matteo Uccelli, Yong Ha Lee, Carolina Rubicondo, Francesca Ciccarese, Stefano Olmi

Background: Laparoscopic BariClip gastroplasty (LBCG) is a new reversible bariatric procedure designed to replicate the restrictive effects of laparoscopic sleeve gastrectomy (LSG) by placing a clip vertically on the stomach. This technique achieves gastric lumen restriction without the need for resection, ensuring organ preservation and reversibility. However, concerns have arisen regarding potential complications such as gastroesophageal reflux disease (GERD), slippage, or erosion of the stomach. The aim of the study is to evaluate the outcomes and complications of LBCG.

Methods: This is a monocentric retrospective study. We analyzed 149 patients who underwent LBCG procedure between July 2021 and November 2023. A minimum follow-up period of 6 months was observed for all patients, recording clinically relevant GERD through GERD-Q score questionnaires. Weight loss was monitored through body mass index (BMI) and % total weight loss (%TWL), registered during follow-up visits.

Results: Overall, 149 patients were eligible for this study. Overall complication rate was 8% (12/149). The average BMI went from 40 ± 4.37 kg/m2 to 28 ± 4.29 kg/m2 (p < 0.05) in 6 months, while the mean %TWL was 22.6% after at least 6 months of follow-up. Clinically relevant GERD went from 18.1% (27/149) to 10.7% (16/149), p = 0.1262. As expected, also the PPI usage was not altered significantly (17.8% vs 16.4%), p = 0.8714.

Conclusions: LBCG remains an experimental procedure that must be approached with caution. Nonetheless, the potential of LBCG to reproduce the effects of LSG while reducing GERD makes it a promising new reversible option for the treatment of morbid obesity.

背景:腹腔镜巴氏胃成形术(LBCG)是一种新型可逆减肥手术,旨在通过在胃部垂直放置一个夹子,复制腹腔镜袖带胃切除术(LSG)的限制效果。该技术无需切除胃,即可实现胃腔限制,从而确保器官的保留和可逆性。然而,人们对胃食管反流病(GERD)、胃滑脱或胃侵蚀等潜在并发症产生了担忧。本研究旨在评估 LBCG 的效果和并发症:这是一项单中心回顾性研究。我们分析了 2021 年 7 月至 2023 年 11 月间接受 LBCG 手术的 149 名患者。我们对所有患者进行了至少 6 个月的随访,通过 GERD-Q 评分问卷记录了临床相关的胃食管反流情况。体重减轻情况通过体重指数(BMI)和总体重减轻百分比(%TWL)进行监测,并在随访期间进行登记:共有 149 名患者符合研究条件。总并发症发生率为 8%(12/149)。平均体重指数(BMI)从 40 ± 4.37 kg/m2 降至 28 ± 4.29 kg/m2(p 结论:LBCG 仍然是一种实验性手术,但它可以帮助患者减轻体重:LBCG 仍然是一种实验性手术,必须谨慎对待。不过,LBCG 有可能在减少胃食管反流的同时再现 LSG 的效果,这使其成为治疗病态肥胖症的一种很有前途的可逆性新选择。
{"title":"BariClip: Outcomes and Complications from a Single-Center Experience.","authors":"Marta Bonaldi, Matteo Uccelli, Yong Ha Lee, Carolina Rubicondo, Francesca Ciccarese, Stefano Olmi","doi":"10.1007/s11695-024-07522-9","DOIUrl":"10.1007/s11695-024-07522-9","url":null,"abstract":"<p><strong>Background: </strong>Laparoscopic BariClip gastroplasty (LBCG) is a new reversible bariatric procedure designed to replicate the restrictive effects of laparoscopic sleeve gastrectomy (LSG) by placing a clip vertically on the stomach. This technique achieves gastric lumen restriction without the need for resection, ensuring organ preservation and reversibility. However, concerns have arisen regarding potential complications such as gastroesophageal reflux disease (GERD), slippage, or erosion of the stomach. The aim of the study is to evaluate the outcomes and complications of LBCG.</p><p><strong>Methods: </strong>This is a monocentric retrospective study. We analyzed 149 patients who underwent LBCG procedure between July 2021 and November 2023. A minimum follow-up period of 6 months was observed for all patients, recording clinically relevant GERD through GERD-Q score questionnaires. Weight loss was monitored through body mass index (BMI) and % total weight loss (%TWL), registered during follow-up visits.</p><p><strong>Results: </strong>Overall, 149 patients were eligible for this study. Overall complication rate was 8% (12/149). The average BMI went from 40 ± 4.37 kg/m<sup>2</sup> to 28 ± 4.29 kg/m<sup>2</sup> (p < 0.05) in 6 months, while the mean %TWL was 22.6% after at least 6 months of follow-up. Clinically relevant GERD went from 18.1% (27/149) to 10.7% (16/149), p = 0.1262. As expected, also the PPI usage was not altered significantly (17.8% vs 16.4%), p = 0.8714.</p><p><strong>Conclusions: </strong>LBCG remains an experimental procedure that must be approached with caution. Nonetheless, the potential of LBCG to reproduce the effects of LSG while reducing GERD makes it a promising new reversible option for the treatment of morbid obesity.</p>","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A False Dichotomy: Rethinking the Debate Around Pharmacotherapy vs Bariatric Metabolic Surgery in Obesity Treatment. 错误的二分法:反思肥胖症治疗中药物疗法与减肥代谢手术的争论。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1007/s11695-024-07537-2
Larne Jones-Whiting, Mohammed Aradaib, Kamal Mahawar
{"title":"A False Dichotomy: Rethinking the Debate Around Pharmacotherapy vs Bariatric Metabolic Surgery in Obesity Treatment.","authors":"Larne Jones-Whiting, Mohammed Aradaib, Kamal Mahawar","doi":"10.1007/s11695-024-07537-2","DOIUrl":"10.1007/s11695-024-07537-2","url":null,"abstract":"","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validity of Continuous Glucose Monitoring for the Diagnosis of Dumping Syndrome After Metabolic Surgery, in Comparison to the Oral Glucose Tolerance Test. 连续葡萄糖监测与口服葡萄糖耐量试验在诊断代谢手术后倾倒综合征方面的有效性比较。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-22 DOI: 10.1007/s11695-024-07530-9
Bethan Price, Monelle Bertrand, Ana Estrade, Pierre Brinas, Géraud Tuyeras, Eric Guillaume, Stéphane Bordes, Emilie Montastier, Hélène Hanaire, Patrick Ritz

Purpose: Dumping syndrome (DS) is a common complication of metabolic surgery, occurring in as many as 40% of bariatric patients. The reference diagnostic test is oral glucose tolerance testing (OGTT) which is often poorly tolerated and may induce false positive results. Continuous glucose monitoring (CGM) is better tolerated and can monitor patients for about 2 weeks in everyday life. This study aimed at testing the diagnostic capacity of CGM in patients with and without DS, as validated by OGTT.

Material and methods: This is a retrospective monocentric study including adults after bariatric surgery, who complained of DS-compatible symptoms and who had OGTT. CGM characteristics were compared in DS-positive (n = 37) and DS-negative patients (n = 14).

Results: None of the CGM parameters differed between the two groups: mean, variability, time in range, and time above or below range. OGTT induced different hematocrit and pulse rate responses (by DS definition) but no difference in blood glucose values.

Conclusion: Despite being a better-tolerated test than OGTT, CGM should not be recommended for the diagnosis of DS. It may still be useful for monitoring glucose values in everyday life to help patients modify their diet, when DS is caused by carbohydrates with high glycemic index. The reference diagnostic test for dumping syndrome is poorly tolerated and artificial. CGM is useful in everyday life, and changes in glucose might be a signal of dumping syndrome. However, CGM is not a valid diagnostic test for dumping syndrome.

目的:倾倒综合征(DS)是代谢手术的常见并发症,多达 40% 的减肥患者会出现这种情况。参考诊断测试是口服葡萄糖耐量测试(OGTT),这种测试通常耐受性较差,并可能导致假阳性结果。连续葡萄糖监测(CGM)的耐受性较好,可在日常生活中对患者进行约两周的监测。本研究旨在测试 CGM 对 DS 患者和非 DS 患者的诊断能力,并通过 OGTT 进行验证:这是一项回顾性单中心研究,研究对象包括接受过减肥手术、主诉有 DS 相关症状并进行过 OGTT 的成人。比较了 DS 阳性患者(37 人)和 DS 阴性患者(14 人)的 CGM 特征:结果:两组患者的 CGM 参数均无差异:平均值、变异性、在范围内的时间、高于或低于范围的时间。OGTT 引起了不同的血细胞比容和脉率反应(根据 DS 定义),但血糖值没有差异:结论:尽管 CGM 是一种比 OGTT 更好耐受的测试,但不应推荐用于 DS 的诊断。如果 DS 是由高升糖指数的碳水化合物引起的,那么 CGM 仍可用于监测日常生活中的血糖值,帮助患者调整饮食。倾倒综合征的参考诊断测试耐受性差,而且是人为的。CGM 在日常生活中很有用,血糖变化可能是倾倒综合征的信号。然而,血糖监测仪并非倾倒综合征的有效诊断测试。
{"title":"Validity of Continuous Glucose Monitoring for the Diagnosis of Dumping Syndrome After Metabolic Surgery, in Comparison to the Oral Glucose Tolerance Test.","authors":"Bethan Price, Monelle Bertrand, Ana Estrade, Pierre Brinas, Géraud Tuyeras, Eric Guillaume, Stéphane Bordes, Emilie Montastier, Hélène Hanaire, Patrick Ritz","doi":"10.1007/s11695-024-07530-9","DOIUrl":"10.1007/s11695-024-07530-9","url":null,"abstract":"<p><strong>Purpose: </strong>Dumping syndrome (DS) is a common complication of metabolic surgery, occurring in as many as 40% of bariatric patients. The reference diagnostic test is oral glucose tolerance testing (OGTT) which is often poorly tolerated and may induce false positive results. Continuous glucose monitoring (CGM) is better tolerated and can monitor patients for about 2 weeks in everyday life. This study aimed at testing the diagnostic capacity of CGM in patients with and without DS, as validated by OGTT.</p><p><strong>Material and methods: </strong>This is a retrospective monocentric study including adults after bariatric surgery, who complained of DS-compatible symptoms and who had OGTT. CGM characteristics were compared in DS-positive (n = 37) and DS-negative patients (n = 14).</p><p><strong>Results: </strong>None of the CGM parameters differed between the two groups: mean, variability, time in range, and time above or below range. OGTT induced different hematocrit and pulse rate responses (by DS definition) but no difference in blood glucose values.</p><p><strong>Conclusion: </strong>Despite being a better-tolerated test than OGTT, CGM should not be recommended for the diagnosis of DS. It may still be useful for monitoring glucose values in everyday life to help patients modify their diet, when DS is caused by carbohydrates with high glycemic index. The reference diagnostic test for dumping syndrome is poorly tolerated and artificial. CGM is useful in everyday life, and changes in glucose might be a signal of dumping syndrome. However, CGM is not a valid diagnostic test for dumping syndrome.</p>","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of ICG During the SADI-S Procedure. ICG 在 SADI-S 过程中的作用。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-23 DOI: 10.1007/s11695-024-07531-8
Guillermo Borjas, Andrés Sánchez Pernaute, Antonio Torres, Carlos Ferrigni, Jorge Guillen, Eduardo Ramos, Ali Urdaneta

Indocyanine green (ICG) is a nontoxic, fluorescent iodide dye with rapid hepatic clearance that has been used in medical applications since the mid-1950s. In abdominal surgery, ICG can be used to identify anatomical structures such as the biliary tract, urinary tract, blood vessels, tissue perfusion on different organs, or anastomosis in the digestive system. The application of ICG during bariatric surgery may be useful in primary and revisional procedures at different steps of the surgery. The purpose of this study is to examine the role of indocyanine green during the SADI-S procedure and to highlight the key aspects of this procedure. We present a case series of 22 patients with morbid obesity who underwent a multidisciplinary evaluation and were selected for the SADI-S procedure via a laparoscopic approach. The ICG dose and timing were as recommended in the International Society for Fluorescence Guided Surgery guidelines. For arteriography, 3 ml (7.5 mg) was used, and the detection time was 30-60 s after intravenous administration. For visualization of the common bile duct, we used 1 ml (2.5 mg) applied intravenously at least 45 min before the procedure. For the leak test, a dilution of 1 ml (2.5 mg) of ICG + 5 ml of methylene blue in 100 cc of sterile water, which was prepared just before the test, was used, and the mixture was passed through an orogastric tube. We expose the surgical steps in which ICG can improve outcomes or prevent complications when performing the SADI-S procedure. Key Points • The role of ICG during SADI-S is described. • The step-by-step results of ICG during the SADI-S procedure are highlighted. • ICG was shown to be safe and useful during bariatric surgery in morbidly obese patients.

吲哚菁绿(ICG)是一种无毒、可快速肝清除的荧光碘染料,自 20 世纪 50 年代中期以来一直用于医疗用途。在腹部手术中,ICG 可用于识别解剖结构,如胆道、泌尿道、血管、不同器官的组织灌注或消化系统的吻合口。在减肥手术中应用 ICG 可能会在手术不同步骤的初治和复治手术中发挥作用。本研究旨在探讨吲哚菁绿在 SADI-S 手术中的作用,并强调该手术的关键环节。我们对 22 例病态肥胖症患者进行了多学科评估,并选择通过腹腔镜方法进行 SADI-S 手术。ICG 的剂量和时间均按照国际荧光引导手术学会指南的建议。动脉造影使用3毫升(7.5毫克),静脉注射后检测时间为30-60秒。对于胆总管的显像,我们在手术前至少 45 分钟静脉注射 1 毫升(2.5 毫克)。在泄漏测试中,我们使用了 1 毫升(2.5 毫克)ICG + 5 毫升亚甲蓝在 100 毫升无菌水中的稀释液,该稀释液是在测试前刚刚准备好的,然后将混合物通过口胃管。我们揭示了在实施 SADI-S 手术时,ICG 可以改善手术效果或预防并发症的手术步骤。要点 - 介绍 ICG 在 SADI-S 过程中的作用。- 强调了 ICG 在 SADI-S 手术中的作用。- 在病态肥胖患者的减肥手术中,ICG 被证明是安全和有用的。
{"title":"The Role of ICG During the SADI-S Procedure.","authors":"Guillermo Borjas, Andrés Sánchez Pernaute, Antonio Torres, Carlos Ferrigni, Jorge Guillen, Eduardo Ramos, Ali Urdaneta","doi":"10.1007/s11695-024-07531-8","DOIUrl":"10.1007/s11695-024-07531-8","url":null,"abstract":"<p><p>Indocyanine green (ICG) is a nontoxic, fluorescent iodide dye with rapid hepatic clearance that has been used in medical applications since the mid-1950s. In abdominal surgery, ICG can be used to identify anatomical structures such as the biliary tract, urinary tract, blood vessels, tissue perfusion on different organs, or anastomosis in the digestive system. The application of ICG during bariatric surgery may be useful in primary and revisional procedures at different steps of the surgery. The purpose of this study is to examine the role of indocyanine green during the SADI-S procedure and to highlight the key aspects of this procedure. We present a case series of 22 patients with morbid obesity who underwent a multidisciplinary evaluation and were selected for the SADI-S procedure via a laparoscopic approach. The ICG dose and timing were as recommended in the International Society for Fluorescence Guided Surgery guidelines. For arteriography, 3 ml (7.5 mg) was used, and the detection time was 30-60 s after intravenous administration. For visualization of the common bile duct, we used 1 ml (2.5 mg) applied intravenously at least 45 min before the procedure. For the leak test, a dilution of 1 ml (2.5 mg) of ICG + 5 ml of methylene blue in 100 cc of sterile water, which was prepared just before the test, was used, and the mixture was passed through an orogastric tube. We expose the surgical steps in which ICG can improve outcomes or prevent complications when performing the SADI-S procedure. Key Points • The role of ICG during SADI-S is described. • The step-by-step results of ICG during the SADI-S procedure are highlighted. • ICG was shown to be safe and useful during bariatric surgery in morbidly obese patients.</p>","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IFSO Bariatric Endoscopy Committee Evidence-Based Review and Position Statement on Endoscopic Sleeve Gastroplasty for Obesity Management. IFSO 减肥内镜委员会关于内镜袖状胃成形术治疗肥胖症的循证审查和立场声明。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 DOI: 10.1007/s11695-024-07510-z
Barham K Abu Dayyeh, Christine Stier, Aayed Alqahtani, Reem Sharaiha, Mohit Bandhari, Silvana Perretta, Sigh Pichamol Jirapinyo, Gerhard Prager, Ricardo V Cohen
<p><strong>Background: </strong>Obesity is a significant global health issue. Metabolic and bariatric surgery (MBS) is the gold standard in the treatment of obesity due to its proven effectiveness and safety in the short and long term. However, MBS is not suitable for all patients. Some individuals are at high surgical risk or refuse surgical treatment, while others do not meet the criteria for MBS despite having obesity-related comorbidities. This gap has driven the development of endoscopic solutions like endoscopic sleeve gastroplasty (ESG), which offers a less invasive alternative that preserves organ function and reduces risks. A recent IFSO International Delphi consensus study highlighted that multidisciplinary experts agree on the utility of ESG for managing obesity in patients with class I and II obesity and for those with class III obesity who do not wish to pursue or qualify for MBS. This IFSO Bariatric Endoscopy Committee position statement aims to augment these consensus statements by providing a comprehensive systematic review of the evidence and delivering an evidence-based position on the value of ESG within the spectrum of obesity management.</p><p><strong>Methods: </strong>A comprehensive systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Cochrane guidelines.</p><p><strong>Results: </strong>Systematic Review: The systematic review included 44 articles encompassing 15,714 patients receiving ESG. The studies varied from large case series to cohort studies and a randomized controlled trial (RCT). The mean baseline BMI was 37.56 kg/m2. The review focused on weight loss outcomes and safety data.</p><p><strong>Meta-analysis: </strong>Time point Mean %EWL Mean %TBWL 6 months 48.04 15.66 12 months 53.09 17.56 18 months 57.98 16.25 24 months 46.57 15.2 36 months 53.18 14.07 60 months 45.3 15.9 These results demonstrate significant weight loss following ESG.</p><p><strong>Safety: </strong>The pooled serious adverse event (SAE) rate was 1.25%. This low rate of SAEs indicates that ESG is a relatively safe procedure.</p><p><strong>Quality of evidence: </strong>The quality of evidence from the included observational studies was assessed as very low, primarily due to the inherent limitations associated with observational study designs, such as potential biases and lack of randomization. In contrast, the quality of evidence from the single randomized controlled trial was rated as MODERATE, reflecting a more robust study design that provides a higher level of evidence despite some limitations.</p><p><strong>Conclusions: </strong>The IFSO Bariatric Endoscopy Committee, after conducting a comprehensive systematic review and meta-analysis, endorses endoscopic sleeve gastroplasty (ESG) as an effective and valuable treatment for obesity. ESG is particularly beneficial for patients with class I and II obesity, as well as for those with class III obesity who are not suitable candidates for meta
背景:肥胖症是一个重大的全球健康问题。代谢和减肥手术(MBS)是治疗肥胖症的黄金标准,因为它在短期和长期内都被证明是有效和安全的。然而,代谢与减肥手术并不适合所有患者。有些人手术风险高或拒绝手术治疗,而另一些人尽管有肥胖相关的合并症,却不符合减重手术的标准。这种差距推动了内窥镜解决方案的发展,如内窥镜袖状胃成形术(ESG),它提供了一种创伤较小的替代方案,既能保留器官功能,又能降低风险。最近一项 IFSO 国际德尔菲共识研究强调,多学科专家一致认为 ESG 可用于控制 I 级和 II 级肥胖症患者的肥胖症,也可用于那些不希望或不符合 MBS 治疗条件的 III 级肥胖症患者。这份 IFSO 减肥内镜委员会立场声明旨在通过对证据进行全面系统的回顾,并就 ESG 在肥胖症管理范围内的价值提出基于证据的立场,从而加强这些共识声明:方法:按照系统综述和荟萃分析首选报告项目 (PRISMA) 和 Cochrane 指南进行全面系统综述:系统综述:系统综述包括 44 篇文章,涉及 15714 名接受 ESG 治疗的患者。这些研究既有大型病例系列研究,也有队列研究和随机对照试验(RCT)。平均基线体重指数为 37.56 kg/m2。综述重点关注减重结果和安全性数据:6 个月 48.04 15.66 12 个月 53.09 17.56 18 个月 57.98 16.25 24 个月 46.57 15.2 36 个月 53.18 14.07 60 个月 45.3 15.9 这些结果表明 ESG 治疗后体重明显减轻:严重不良事件(SAE)发生率为 1.25%。SAE发生率较低,表明ESG是一种相对安全的治疗方法:纳入的观察性研究的证据质量被评定为很低,这主要是由于观察性研究设计存在固有的局限性,如潜在的偏倚和缺乏随机化。相比之下,单项随机对照试验的证据质量被评为中度,反映出研究设计更加稳健,尽管存在一些局限性,但仍提供了较高水平的证据:IFSO减肥内镜委员会在进行了全面的系统回顾和荟萃分析后,认可内镜袖带胃成形术(ESG)是一种有效且有价值的肥胖症治疗方法。ESG 尤其适用于 I 级和 II 级肥胖症患者,以及不适合进行代谢减肥手术的 III 级肥胖症患者。ESG 的减肥效果显著,安全性良好,严重不良事件发生率低。尽管所纳入的观察性研究存在局限性,但分析中纳入的随机对照试验加强了 ESG 的有效性和安全性,为立场声明提供了循证基础。因此,IFSO 立场声明支持 ESG 在更广泛的肥胖管理中发挥作用,并为其提供了证据基础。
{"title":"IFSO Bariatric Endoscopy Committee Evidence-Based Review and Position Statement on Endoscopic Sleeve Gastroplasty for Obesity Management.","authors":"Barham K Abu Dayyeh, Christine Stier, Aayed Alqahtani, Reem Sharaiha, Mohit Bandhari, Silvana Perretta, Sigh Pichamol Jirapinyo, Gerhard Prager, Ricardo V Cohen","doi":"10.1007/s11695-024-07510-z","DOIUrl":"https://doi.org/10.1007/s11695-024-07510-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Obesity is a significant global health issue. Metabolic and bariatric surgery (MBS) is the gold standard in the treatment of obesity due to its proven effectiveness and safety in the short and long term. However, MBS is not suitable for all patients. Some individuals are at high surgical risk or refuse surgical treatment, while others do not meet the criteria for MBS despite having obesity-related comorbidities. This gap has driven the development of endoscopic solutions like endoscopic sleeve gastroplasty (ESG), which offers a less invasive alternative that preserves organ function and reduces risks. A recent IFSO International Delphi consensus study highlighted that multidisciplinary experts agree on the utility of ESG for managing obesity in patients with class I and II obesity and for those with class III obesity who do not wish to pursue or qualify for MBS. This IFSO Bariatric Endoscopy Committee position statement aims to augment these consensus statements by providing a comprehensive systematic review of the evidence and delivering an evidence-based position on the value of ESG within the spectrum of obesity management.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A comprehensive systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Cochrane guidelines.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Systematic Review: The systematic review included 44 articles encompassing 15,714 patients receiving ESG. The studies varied from large case series to cohort studies and a randomized controlled trial (RCT). The mean baseline BMI was 37.56 kg/m2. The review focused on weight loss outcomes and safety data.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Meta-analysis: &lt;/strong&gt;Time point Mean %EWL Mean %TBWL 6 months 48.04 15.66 12 months 53.09 17.56 18 months 57.98 16.25 24 months 46.57 15.2 36 months 53.18 14.07 60 months 45.3 15.9 These results demonstrate significant weight loss following ESG.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Safety: &lt;/strong&gt;The pooled serious adverse event (SAE) rate was 1.25%. This low rate of SAEs indicates that ESG is a relatively safe procedure.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Quality of evidence: &lt;/strong&gt;The quality of evidence from the included observational studies was assessed as very low, primarily due to the inherent limitations associated with observational study designs, such as potential biases and lack of randomization. In contrast, the quality of evidence from the single randomized controlled trial was rated as MODERATE, reflecting a more robust study design that provides a higher level of evidence despite some limitations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The IFSO Bariatric Endoscopy Committee, after conducting a comprehensive systematic review and meta-analysis, endorses endoscopic sleeve gastroplasty (ESG) as an effective and valuable treatment for obesity. ESG is particularly beneficial for patients with class I and II obesity, as well as for those with class III obesity who are not suitable candidates for meta","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Outcome of the Dutch Common Channel Trial (DUCATI): Preservation of Superior Weight Loss Results Without Significant Malnutrition Side Effects. 荷兰共同通道试验(DUCATI)的长期结果:保持了优异的减肥效果,且无明显的营养不良副作用。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI: 10.1007/s11695-024-07424-w
Ralph P M Gadiot, L Ulas Biter, Pierre G Feskens, Martin Dunkelgrun, Jan A Apers, Gerhard van 't Hof, Guido H H Mannaerts

Purpose: The optimal bowel limb lengths for laparoscopic Roux-en-Y gastric bypass (LRYGB) to maximize weight loss while minimizing nutritional deficiencies in severe obesity treatment remain a topic of debate. The multi-center Dutch Common Channel Trial (DUCATI) aims to compare the outcomes of a very long Roux Limb Roux-en-Y gastric bypass (VLRL-LRYGB) with a standard Roux-en-Y gastric bypass (S-LRYGB).

Methods: A total of 444 patients were randomly assigned in a 1:1, double-blind manner to undergo either VLRL-RYGB or S-LRYGB. Five-year follow-up data were assessed, concentrating on weight loss, obesity-related medical conditions, complications, re-operations, and malnutrition.

Results: Both groups had comparable total alimentary lengths (RL + CC). The VLRL-LRYGB group demonstrated significantly greater %TWL (32.2% vs. 28.6%, p = 0.002) and %EWL (81.2% vs. 70.3%, p = 0.002) at 5 years. Eight (3.6%) patients in the VLRL-LRYGB group versus 2 (0.9%) in the S-LRYGB group (p = 0.055) needed modification surgery for malabsorption. Suboptimal clinical response rate was significantly higher (22.0% vs. 8.3%) in S-LRYGB group. No significant differences for nutrient deficiencies in favor of the S-LRYGB group were found.

Conclusion: A 100-cm common channel with a relatively long Roux limb provides superior, sustainable weight loss over 5 years, without significantly increased rate of malabsorption-related re-operations. These results suggest that a longer Roux limb can still ensure adequate micronutrient uptake in the total alimentary tract. These findings should be considered in discussions regarding the optimal Roux-en-Y limb length for severe obesity treatment.

目的:腹腔镜鲁克斯-en-Y 胃旁路术(LRYGB)在治疗严重肥胖症时,如何最大限度地减轻体重,同时最大限度地减少营养不良,其最佳肠道肢体长度仍是一个争论不休的话题。多中心荷兰共同通道试验(DUCATI)旨在比较超长鲁克斯肢体鲁克斯-Y 胃旁路术(VLRL-LRYGB)与标准鲁克斯-Y 胃旁路术(S-LRYGB)的疗效:共有 444 名患者以 1:1 的双盲方式随机分配接受 VLRL-RYGB 或 S-LRYGB 胃旁路术。对五年的随访数据进行了评估,重点关注体重减轻、肥胖相关疾病、并发症、再次手术和营养不良等情况:结果:两组的消化道总长度(RL + CC)相当。5 年后,VLRL-LRYGB 组的体重减轻率(%TWL)(32.2% 对 28.6%,P = 0.002)和体重减轻率(%EWL)(81.2% 对 70.3%,P = 0.002)明显高于 VLRL-LRYGB 组。VLRL-LRYGB组有8例(3.6%)患者因吸收不良而需要进行改良手术,而S-LRYGB组只有2例(0.9%)(p = 0.055)。S-LRYGB组的次优临床反应率明显更高(22.0% vs. 8.3%)。在营养缺乏方面,S-LRYGB组与S-LRYGB组无明显差异:结论:100 厘米的共同通道和相对较长的鲁克斯肢体可在 5 年内提供卓越的、可持续的减肥效果,而与吸收不良相关的再手术率不会明显增加。这些结果表明,较长的鲁克斯肢体仍能确保整个消化道摄入足够的微量营养素。在讨论治疗重度肥胖症的最佳 Roux-en-Y 断肢长度时,应考虑这些研究结果。
{"title":"Long-term Outcome of the Dutch Common Channel Trial (DUCATI): Preservation of Superior Weight Loss Results Without Significant Malnutrition Side Effects.","authors":"Ralph P M Gadiot, L Ulas Biter, Pierre G Feskens, Martin Dunkelgrun, Jan A Apers, Gerhard van 't Hof, Guido H H Mannaerts","doi":"10.1007/s11695-024-07424-w","DOIUrl":"10.1007/s11695-024-07424-w","url":null,"abstract":"<p><strong>Purpose: </strong>The optimal bowel limb lengths for laparoscopic Roux-en-Y gastric bypass (LRYGB) to maximize weight loss while minimizing nutritional deficiencies in severe obesity treatment remain a topic of debate. The multi-center Dutch Common Channel Trial (DUCATI) aims to compare the outcomes of a very long Roux Limb Roux-en-Y gastric bypass (VLRL-LRYGB) with a standard Roux-en-Y gastric bypass (S-LRYGB).</p><p><strong>Methods: </strong>A total of 444 patients were randomly assigned in a 1:1, double-blind manner to undergo either VLRL-RYGB or S-LRYGB. Five-year follow-up data were assessed, concentrating on weight loss, obesity-related medical conditions, complications, re-operations, and malnutrition.</p><p><strong>Results: </strong>Both groups had comparable total alimentary lengths (RL + CC). The VLRL-LRYGB group demonstrated significantly greater %TWL (32.2% vs. 28.6%, p = 0.002) and %EWL (81.2% vs. 70.3%, p = 0.002) at 5 years. Eight (3.6%) patients in the VLRL-LRYGB group versus 2 (0.9%) in the S-LRYGB group (p = 0.055) needed modification surgery for malabsorption. Suboptimal clinical response rate was significantly higher (22.0% vs. 8.3%) in S-LRYGB group. No significant differences for nutrient deficiencies in favor of the S-LRYGB group were found.</p><p><strong>Conclusion: </strong>A 100-cm common channel with a relatively long Roux limb provides superior, sustainable weight loss over 5 years, without significantly increased rate of malabsorption-related re-operations. These results suggest that a longer Roux limb can still ensure adequate micronutrient uptake in the total alimentary tract. These findings should be considered in discussions regarding the optimal Roux-en-Y limb length for severe obesity treatment.</p>","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric Cancer in One-Anastomosis Mini-gastric Bypass: Case Report and Systematic Review. 单吻合口迷你胃旁路术中的胃癌:病例报告和系统回顾。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-12 DOI: 10.1007/s11695-024-07545-2
Danilo Vinci, Antonio La Terra, Emilio Manno, Giovanni Merola, Andrea Muratore

In the last years, one-anastomosis gastric bypass (OAGB) has been proposed more frequently as obesity surgery technique. Several trials have demonstrated that the easier technical feasibility does not affect the long-term surgical result. However, concern about increased risk of gastric and esophageal cancers has been expressed by several bariatric surgeons. The present study reports the 2nd case of cancer of the gastrointestinal-jejunal anastomosis in a OAGB patient focusing the attention on some technical issues correlated and offering a systematic review of the literature.

近年来,单吻合胃旁路术(OAGB)作为肥胖症手术技术被越来越多地提出。多项试验表明,技术上的简便可行并不会影响长期手术效果。然而,一些减肥外科医生对胃癌和食道癌风险的增加表示担忧。本研究报告了第二例 OAGB 患者胃肠空肠吻合处癌症的病例,重点关注了一些相关的技术问题,并对文献进行了系统回顾。
{"title":"Gastric Cancer in One-Anastomosis Mini-gastric Bypass: Case Report and Systematic Review.","authors":"Danilo Vinci, Antonio La Terra, Emilio Manno, Giovanni Merola, Andrea Muratore","doi":"10.1007/s11695-024-07545-2","DOIUrl":"10.1007/s11695-024-07545-2","url":null,"abstract":"<p><p>In the last years, one-anastomosis gastric bypass (OAGB) has been proposed more frequently as obesity surgery technique. Several trials have demonstrated that the easier technical feasibility does not affect the long-term surgical result. However, concern about increased risk of gastric and esophageal cancers has been expressed by several bariatric surgeons. The present study reports the 2nd case of cancer of the gastrointestinal-jejunal anastomosis in a OAGB patient focusing the attention on some technical issues correlated and offering a systematic review of the literature.</p>","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microencapsulated Oleic Acid for Laxative Effect in Post-Bariatric Surgery and GLP-1 Analogue Patients. 微胶囊油酸对减肥手术后和 GLP-1 类似物患者的通便作用
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-10-19 DOI: 10.1007/s11695-024-07549-y
Liqi Li
{"title":"Microencapsulated Oleic Acid for Laxative Effect in Post-Bariatric Surgery and GLP-1 Analogue Patients.","authors":"Liqi Li","doi":"10.1007/s11695-024-07549-y","DOIUrl":"10.1007/s11695-024-07549-y","url":null,"abstract":"","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Buccal Acupuncture: a Potential Treatment for Postoperative Nausea and Vomiting in Patients Undergoing Metabolic and Bariatric Surgery. 颊针:代谢和减肥手术患者术后恶心和呕吐的潜在治疗方法。
IF 2.9 3区 医学 Q1 SURGERY Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1007/s11695-024-07513-w
Kai-Jing Liu, Yanjun Chen, Wah Yang, Xue-Mei Peng
{"title":"Buccal Acupuncture: a Potential Treatment for Postoperative Nausea and Vomiting in Patients Undergoing Metabolic and Bariatric Surgery.","authors":"Kai-Jing Liu, Yanjun Chen, Wah Yang, Xue-Mei Peng","doi":"10.1007/s11695-024-07513-w","DOIUrl":"10.1007/s11695-024-07513-w","url":null,"abstract":"","PeriodicalId":19460,"journal":{"name":"Obesity Surgery","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Obesity Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1